Cancer Family
Pancreaticobiliary Neoplasm
CI-CAN-00000309Explore in graph →
Non-malignant1,205 active trials11 approved drugs92 evidence items
- NCIt
- C223357
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000309Explore in graph →
Clinical trials
5,005 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06960122 | Clinical Study on Fecal Microbiota Transplantation for Diarrhea After Total Pancreatectomy(FMT-TP) | not yet recruiting | N/A | 10 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT02983578 | Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer | active not recruiting | Phase 2 | 39 | M.D. Anderson Cancer Center |
| 1 |
| May 6, 2025 |
| clinicaltrials |
| NCT05179824 | Tempus Priority Study: A Pan-tumor Observational Study | active not recruiting | — | 1,000 | Tempus AIINDUSTRY | 1 | May 6, 2025 | clinicaltrials |
| NCT06956716 | Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 1 / Phase 2 | 30 | Zhejiang UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT06954753 | Predicting Cancer in Pancreatic Cystic Lesions Through Artificial Intelligence | not yet recruiting | — | 250 | Centre Hospitalier Universitaire de NiceOTHER | 0 | May 2, 2025 | clinicaltrials |
| NCT04037007 | Efficacy of Fistulotomy for Biliary Cannulation | recruiting | N/A | 320 | Coordinación de Investigación en Salud, MexicoOTHER_GOV | 1 | May 1, 2025 | clinicaltrials |
| NCT04503265 | A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 122 | AtlasMedx, IncorporatedINDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT06121622 | Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours(3DPanNET) | recruiting | — | 70 | IRCCS San RaffaeleOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT05827796 | IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 70 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06940778 | LIQUID BIOPSY FOCUSING ON CIRCULATING TUMOR CELLS AND CIRCULATING TUMOR DNA AS PRECISION MEDICINE IN GASTROINTESTINAL TUMORS(BLENTI) | active not recruiting | — | 273 | Hospital do CoracaoOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06945978 | Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer (mirPANC 2)(mirPANC 2) | recruiting | — | 60 | Benedito Mauro RossiOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06946849 | Second-line Regimen Combined With Radiotherapy Versus Without Radiotherapy in Patients With Locally Advanced/Oligometastatic ICC After Failure of First-line Treatment：an Open-label, Randomized, Controlled Phase II Clinical Study(SED-RO-ICC) | not yet recruiting | Phase 2 | 76 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT05736731 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression(EVEREST-1) | active not recruiting | Phase 1 / Phase 2 | 160 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06944587 | A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer(NORPACT-3) | recruiting | — | 400 | Oslo University HospitalOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06583993 | A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α srRNA in Treating Advanced ICC Patients | recruiting | Early Phase 1 | 9 | Shanghai Changzheng HospitalOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT06822413 | Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis | recruiting | — | 600 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT06938906 | Multimodal Therapy Impact on Pancreatic Cancer Survival(MMTIPS) | active not recruiting | — | 405 | National Cheng Kung UniversityOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT05342194 | Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study | recruiting | Phase 3 | 480 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06162468 | Feasibility Trial of EUS-PCA in IPMN Pancreatic Cysts | not yet recruiting | N/A | 20 | University of Auckland, New ZealandOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT05518643 | Compliance With ERAS Protocol in Pancreatic Surgery, Stress Response and Outcomes | recruiting | — | 120 | University of ThessalyOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06937112 | 18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis | recruiting | — | 20 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06938503 | AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer | not yet recruiting | Phase 2 | 48 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Apr 22, 2025 | clinicaltrials |
| NCT05919537 | Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | active not recruiting | Phase 1 | 68 | Hummingbird BioscienceINDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06532331 | A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer | active not recruiting | Phase 1 | 87 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT04634058 | PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment | active not recruiting | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT05083780 | Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer | active not recruiting | Phase 1 | 40 | Changhoon YooOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT05915351 | Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC) | active not recruiting | Phase 2 | 28 | University of Kansas Medical CenterOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06712420 | Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB)(NEOGB) | recruiting | Phase 3 | 114 | Rajiv Gandhi Cancer Institute & Research Center, IndiaOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06355427 | The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma(FAPIChol) | recruiting | Phase 2 / Phase 3 | 81 | Mara Veenstra, MDOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT06760364 | A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer(CHAMPION) | recruiting | Phase 1 | 21 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06920082 | Progressive Muscle Relaxation Exercises on Sleep, Fatigue and Pain in Pancreatic and Colon Cancer Patients | active not recruiting | N/A | 60 | Istanbul Sabahattin Zaim UniversityOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06860477 | Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01) | recruiting | Phase 2 | 92 | Fudan UniversityOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06913218 | A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC | not yet recruiting | Phase 1 | 60 | AkesoINDUSTRY | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06914674 | Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas(SPTP) | recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06911021 | 68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma | not yet recruiting | N/A | 20 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06779318 | Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis | not yet recruiting | Phase 4 | 464 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06899854 | Collection of Blood and Tissue Samples From Patients With Primary Liver Cancer. | recruiting | — | 53 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT05298722 | Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial)(PeRFormanCe) | recruiting | N/A | 45 | University Hospital, GhentOTHER | 2 | Apr 2, 2025 | clinicaltrials |
| NCT02170090 | Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer(ACTICCA-1) | active not recruiting | Phase 3 | 789 | Universitätsklinikum Hamburg-EppendorfOTHER | 8 | Mar 30, 2025 | clinicaltrials |
| NCT06903273 | Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma(TisGCS for BTC) | not yet recruiting | Phase 2 | 35 | National Cheng-Kung University HospitalOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT05551299 | Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy(CARP) | recruiting | Phase 4 | 258 | University of LeipzigOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT05776524 | Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer | recruiting | Phase 2 | 46 | THERABIONIC INC.OTHER | 1 | Mar 25, 2025 | clinicaltrials |
| NCT05653453 | Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer | recruiting | Phase 3 | 512 | Jiangsu Healthy Life Innovation Medical Technology Co., LtdINDUSTRY | 1 | Mar 24, 2025 | clinicaltrials |
| NCT02818829 | Biological and Clinical Database for Pancreatic Adenocarcinoma(BACAP) | active not recruiting | — | 1,700 | University Hospital, ToulouseOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06638866 | AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort(AI-PANC) | recruiting | — | 5,000 | Changhai HospitalOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06883539 | A Phase I Study of LXP1788 Injection with Advanced Solid Tumors. | recruiting | Phase 1 | 24 | LaunXP Biomedical Co., Ltd.INDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06757244 | DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer(DOVIPA) | recruiting | Phase 2 | 35 | Hopital FochOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06707025 | The Expression of CD24 "do-not-eat-me" Signal in Cholangiocarcinoma(CD24CCA) | active not recruiting | — | 50 | Hadassah Medical OrganizationOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT02867865 | Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers(POLCAGB) | active not recruiting | Phase 2 / Phase 3 | 124 | Tata Memorial HospitalOTHER_GOV | 1 | Mar 13, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 7, 2025source: clinicaltrials